Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - ALLERGAN PLC

23 Nov 2015 15:28

RNS Number : 6636G
FIL Limited
23 November 2015
Β 

ο»Ώ

Β 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,TAKEOVER RULES, 2007 (AS AMENDED)

Β 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIESREPRESENTING 1% OR MORE

Β 

1. KEY INFORMATION

Β 

Name of person dealing (Note 1)

FMR LLC and/or one or more of its direct or indirect subsidiaries

And

FIL Limited and/or one or more of its direct and indirect subsidiaries

Β 

Company dealt in

ALLERGAN PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares and preferred convertible stock

Β 

Date of dealing

20-November-15

Β 

2. INTERESTS AND SHORT POSITIONS

Β 

(a) Interests and short positions (following dealing) in the class of relevant securitydealt in (Note 3)

Β 

Ordinary Shares

Β 

Long

Short

Β 

Β 

Number (%)

Number (%)

(1) Relevant securities

Β 

15,866,420 4.02%

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Β 

Total

Β 

15,866,420 4.02%

The above position includes a transfer in of 4 shares.

Β 

Β 

Preferred Convertible Stock

Β 

Long

Short

Β 

Β 

Number (%)

Number (%)

(1) Relevant securities

Β 

264,604 5.22%

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Β 

Total

Β 

264,604 5.22%

Β 

Β 

(b) Interests and short positions in relevant securities of the company, other than theclass dealt in (Note 3)

Β 

Class of relevant security:

Β 

Long

Short

Β 

Β 

Number (%)

Number (%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Total

Β 

Β 

3. DEALINGS (Note 4)

Β 

(a) Purchases and sales

Β 

Purchase/sale

Β 

Number of securities

Price per unit

Buy

6,300

308.55 USD/ Share

Buy

800

309.09 USD/ Share

Sale

20,579

310.33 USD/ Share

Sale

6,300

308.55 USD/ Share

Sale

18,300

309.93 USD/ Share

Buy

990

302.37 USD/ Share

Buy

48

302.76 USD/ Share

Buy

51

301.85 USD/ Share

Sale

15

302.99 USD/ Share

Sale

4

303.23 USD/ Share

Sale

9

305.00 USD/ Share

Sale

5

302.20 USD/ Share

Sale

2

302.9933 USD/ Share

Sale

2

302.655 USD/ Share

Sale

9

302.21 USD/ Share

Buy (preferred convertible stock 2.8345 conversion factor)

300

1,044.00 USD/ Share

Buy (preferred convertible stock 2.8345 conversion factor)

1,370

1,038.56 USD/ Share

Buy (preferred convertible stock 2.8345 conversion factor)

4,600

1,033.1 USD/ Share

Β 

(b) Derivatives transactions (other than options transactions)

Β 

Product name,

e.g. CFD

Nature of transaction (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

Β 

Β 

Β 

Β 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Β 

Product name,

e.g. call option

Β 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 5)

Β 

Β 

(ii) Exercising

Β 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

Β 

Β 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Β 

Nature of transaction (Note 8)

Β 

Details

Price per unit (if applicable) (Note 5)

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

Β 

Is a Supplemental Form 8 attached? (Note 9) No

Β 

Β 

Date of disclosure

23-November-15

Contact name

Sally-Ann Hatton

Telephone number

01737 837148

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISELLFFELDLVFIE
Date   Source Headline
19th May 201412:59 pmRNSForm 8.3 - AstraZeneca Plc
19th May 201412:53 pmRNSForm 8.3 - Pfizer Inc
19th May 201412:50 pmRNSForm 8.3 - Pfizer Inc
19th May 201412:24 pmRNSForm 8.5 (EPT/NON-RI) Replacement
19th May 201412:19 pmRNSForm 8.5 (EPT/RI)
19th May 201412:04 pmRNSForm 8.3 - Pfizer Inc
19th May 201411:32 amRNSForm 8.5 (EPT/NON-RI)
19th May 201411:19 amRNSForm 8.5 (EPT/RI)
19th May 201411:18 amRNSForm 8 (DD) - [Pfizer Inc]
19th May 201411:16 amBUSForm 8.3 - Pfizer Inc
19th May 201411:12 amRNSForm 8.5 (EPT/RI) Pfizer Inc
19th May 201411:10 amRNSForm 8.5 (EPT/RI) Pfizer Inc
19th May 201411:09 amRNSForm 8.5 (EPT/RI) Pfizer Inc
19th May 201410:50 amRNSForm 8.5 (EPT/RI) - Pfizer
19th May 20149:22 amRNSRule 2.10 Announcement
19th May 20147:08 amRNSASTRAZENECA BOARD REJECTS PFIZER'S FINAL PROPOSAL
19th May 20147:00 amRNSPFIZER MAKES FINAL PROPOSAL TO ASTRAZENECA
19th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
16th May 20145:00 pmRNSForm 8.3 - Replacement Pfizer Inc
16th May 20144:59 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
16th May 20144:57 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
16th May 20144:33 pmRNSForm 8 (DD) - Pfizer Inc.
16th May 20144:27 pmRNSForm 8.5 (EPT/NON-RI)Amendment
16th May 20144:19 pmRNSForm 8.5 (EPT/NON-RI)
16th May 20143:39 pmRNSForm 8 (DD) - [Pfizer Inc]
16th May 20143:39 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
16th May 20143:34 pmRNSForm 8.3 - Pfizer Inc
16th May 20143:12 pmBUSForm 8.3 - Pfizer Inc
16th May 20143:03 pmRNSForm 8.3 - Pfizer Inc.
16th May 20142:57 pmRNSForm 8.3 - [PFIZER INC]
16th May 20142:39 pmRNSForm 8.3 - Pfizer Inc
16th May 20142:39 pmRNSForm 8.3 - Pfizer Inc.
16th May 20142:38 pmBUSForm 8.3 - Pfizer Inc.
16th May 20142:33 pmBUSForm 8.3 - Pfizer Inc
16th May 20142:32 pmRNSForm 8.3 - [AstraZeneca Plc]
16th May 20142:31 pmRNSForm 8.3 - [Pfizer Inc]
16th May 20141:53 pmBUSForm 8.3 - Pfizer Inc.
16th May 20141:34 pmRNSForm 8.3 - Pfizer Inc
16th May 201412:57 pmBUSForm 8.3 - Pfizer Inc
16th May 201412:33 pmRNSForm 8.3 - [Pfizer Inc]
16th May 201412:32 pmRNSForm 8.5 (EPT/RI)AMENDMENTS
16th May 201412:27 pmRNSForm 8.3 - Pfizer Inc
16th May 201412:26 pmRNSForm 8.3 - Pfizer Inc
16th May 201412:24 pmRNSForm 8.3 - AstraZeneca Plc
16th May 201412:24 pmRNSForm 8.3 - AstraZeneca Plc
16th May 201412:01 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
16th May 201411:55 amRNSForm 8.3 - Pfizer Inc
16th May 201411:54 amRNSForm 8.5 (EPT/RI) - Pfizer Inc.
16th May 201411:40 amRNSForm 8.5 (EPT/RI) Pfizer Inc
16th May 201411:34 amRNSForm 8.5 (EPT/RI) Pfizer Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.